ABBOTT INDIA LIMITED
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Abbott
- Target Recruit Count
- 56
- Registration Number
- NCT00941746
- Locations
- 🇳🇱
Site Ref # / Investigator 51568, Utrecht, Netherlands
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
- Conditions
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 38
- Registration Number
- NCT00931281
- Locations
- 🇺🇸
Site Reference ID/Investigator# 18161, Waukegan, Illinois, United States
A Study of Single Dose of ABT-333 in Healthy Male Adults
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2010-10-25
- Lead Sponsor
- Abbott
- Target Recruit Count
- 39
- Registration Number
- NCT00919490
- Locations
- 🇯🇵
Site Reference ID/Investigator# 19102, Kagoshima, Japan
Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Abbott
- Target Recruit Count
- 154
- Registration Number
- NCT00918255
- Locations
- 🇳🇱
Site Ref # / Investigator 18470, Amsterdam, Netherlands
🇺🇸Site Ref # / Investigator 18209, Atlanta, Georgia, United States
🇩🇰Site Ref # / Investigator 18683, Copenhagen NV, Denmark
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 150
- Registration Number
- NCT00918450
Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 10
- Registration Number
- NCT00912431
- Locations
- 🇺🇸
Site Reference ID/Investigator# 20761, Glendale, California, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT00909636
- Locations
- 🇺🇸
Site Reference ID/Investigator# 20081, Waukegan, Illinois, United States
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 8
- Registration Number
- NCT00909311
- Locations
- 🇺🇸
Site Reference ID/Investigator# 19421, Waukegan, Illinois, United States
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 34
- Registration Number
- NCT00895102
- Locations
- 🇺🇸
Site Reference ID/Investigator# 19441, Waukegan, Illinois, United States
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
- Conditions
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 100
- Registration Number
- NCT00891813
- Locations
- 🇵🇪
Site Reference ID/Investigator# 21401, Callao, Peru
🇵🇪Site Reference ID/Investigator# 23857, Lima, Peru
🇵🇪Site Reference ID/Investigator# 10941, Lima, Peru